Stock Analiz

Nuvectis Pharma, Inc. NVCT

Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026

$20.24Market cap $696M
Open the interactive analysis →

Nuvectis Pharma, Inc. (NVCT) is a healthcare company listed in the US with a market value of about $696M.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -134%.

About Nuvectis Pharma

Nuvectis Pharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2022. It was profitable in 0 of the last 5 years in our data. Its share count rose by 72% over three years (dilution for shareholders).

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B5.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-133.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal year20252024202320222021
Revenue—————
Net income-$26M-$19M-$22M-$19M-$13M
Free cash flow—————
EPS (diluted)$-1.32$-1.11$-1.43$-1.51$-3.02
Net margin—————
ROIC-118.3%-161.4%-148.3%-106.9%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $35.40, 75% above the current price; targets range from $30.00 to $40.00; the consensus rating is “Strong buy”; expected EPS is $-2.03 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Nuvectis Pharma pay a dividend?

Not currently.

Is Nuvectis Pharma a good stock to buy?

We do not give buy or sell advice. Nuvectis Pharma scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.